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Abstract
Although HIV-1 Vpr displays several functions in vitro, limited information exists concerning their relevance during infection.
Here, we characterized Vpr variants isolated from a rapid and a long-term non-progressor (LTNP). Interestingly, vpr alleles
isolated from longitudinal samples of the LTNP revealed a dominant sequence that subsequently led to diversity similar to
that observed in the progressor patient. Most of primary Vpr proteins accumulated at the nuclear envelope and interacted
with host-cell partners of Vpr. They displayed cytostatic and proapoptotic activities, although a LTNP allele, harboring the
Q65R substitution, failed to bind the DCAF1 subunit of the Cul4a/DDB1 E3 ligase and was inactive. This Q65R substitution
correlated with impairment of Vpr docking at the nuclear envelope, raising the possibility of a functional link between this
property and the Vpr cytostatic activity. In contradiction with published results, the R77Q substitution, found in LTNP alleles,
did not influence Vpr proapoptotic activity.
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Introduction
Like for other ÆÆ auxiliary ææ proteins of HIV-1, it has been
suggested that Vpr is important in vivo for virus replication and
pathogenesis(seeRef. [1]forreview). TheHIV-1 vprgene encodesa
14 kDa protein and is one of the most highly conserved genes
among primary isolates of human and simian immunodeficiency
viruses (SIV). Vpr is found in HIV-1 virions, in infected cells, but
also in sera and cerebro-spinal fluid of AIDS patients, suggesting
that it participates in various aspects of the biology of HIV-1. The
role of Vpr in vivo has been investigated in rhesus macaques infected
with SIVmac, and it was initially shown that monkeys infected with
SIV lacking the vpr and the related vpx genes displayed a lower virus
burden and did not consistently develop immunodeficiency disease
[2,3]. Despite these observations, the exact contributions of Vpr
during the natural course of infection are still elusive.
Several functions have been attributed to HIV-1 Vpr in vitro,
including an effect on the reverse-transcription process, nuclear
import of the viral DNA, cell cycle arrest at the G2/M transition,
induction of apoptosis and transactivation of the HIV-1 LTR (see
Ref. [1] for review). While its role in the reverse transcription
process implies interaction with the nuclear form of the DNA
repair enzyme UNG2 for modulation of the virus mutation rate
[4–6], it was suggested that Vpr participates in the DNA nuclear
import process through docking to the nuclear envelope (NE) by
interaction with components of the nuclear pore complex [7–10],
such as the nucleoporin hCG1. While these properties of Vpr have
been shown to contribute to virus replication in non-dividing cells
[10,11], Vpr-induced G2-arrest, which is consequent to its
interaction with the DCAF1 subunit of the Cul4a/DDB1 E3
ubiquitin ligase [12–17], may provide a favorable cellular
environment for HIV-1 transcription [18]. In addition, the
proapoptotic activity of Vpr has been postulated to contribute to
the depletion of CD4+ T cells observed in infected patients.
Although numerous studies have demonstrated that mutations in
HIV-1 Vpr could dramatically affect its known functions [19–21],
these mutations were artificially created and did not represent the
profile of naturally occurring mutations throughout the course of
infection. While only a few genotypic analyses of the vpr alleles
isolated from HIV-1 infected patients have been performed, there is
no report regarding the functional characterization of primary Vpr
variants during the course of infection. Nevertheless, an initial study
has reported that a single substitution at the position Arg77 of HIV-
1 Vpr(Arg77Gln)was found ina higherfrequencyinvprallelesfrom
long-term non-progressors (LTNPs) than in patients with AIDS
[22]. While Mologni et al. confirmed this observation [23], several
other groups did not find any association of the R77Q substitution
with the prognosis of disease progression [24–28].
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7514The present study aimed at analyzing the molecular and
functional properties of primary Vpr proteins isolated from two
infected patients, in terms of binding to its known cellular partners,
docking at the NE, cytostatic and proapoptotic activities. In
particular, a longitudinal analysis of Vpr variants isolated from a
long-term non-progressor (LTNP) was performed.
Results and Discussion
Molecular analysis of vpr alleles
Peripheral blood mononuclear cells (PBMCs) from the LTNP
patient were sampled in 1986, 1996 and 2004 (i.e. 1, 11 and 19
years after infection) for longitudinal analysis of vpr alleles, and a
single PBMC sample from a progressor patient was analyzed
(Fig. 1A). Vpr genes were amplified by PCR from the cellular DNA
and cloned into a shuttle plasmid for genotypic analysis. DNA
sequences from 40 independent clones recovered from two
independent PCR were determined for each sample, allowing
identification of the most represented vpr alleles from viral
quasispecies. The relative frequency of the primary vpr alleles
identified is recapitulated in Table 1. The first two samples
analyzed from the LTNP, namely LTNP-86 and LTNP-96
(GenBank Accession numbers GU014240 and GU014241,
respectively), showed a single vpr sequence sharing 95% a.a.
identity (Fig. 1B), that subsequently evolved in a genetic diversity
(LTNP-04-1 to -04-5; GenBank Accession numbers GU014242,
GU014243, GU014244, GU014245 and GU014246, respectively)
similar to that observed in the progressor patient (PR-1, PR-2 and
PR-3; GenBank Accession numbers GU014237, GU014238 and
GU014239, respectively). Notably, the sequence diversity of the
LTNP-04 alleles correlated with an increase of the plasma viral
load that paralleled a slight decline of the CD4+ T-cell count
(Fig. 1A). This decrease of the CD4+ T-cells was still apparent in
recent blood samples from 2005 and 2007, and bulk genotypic
analysis of vpr from these samples (LTNP-05 and -07) showed that
the LTNP-04-1 vpr sequence was still predominant at those times
(Fig. 1B). This increase in HIV-1 diversity might be related to an
increase in viral fitness, which in turn is a determining factor in
infection progression [29–32].
Interestingly, vpr alleles from LTNP-86 and LTNP-04 samples
all contained a R77Q substitution, previously reported as
deleterious for Vpr proapoptotic activity [22,23], whereas
LTNP-96 showed an Arg at this position (Fig. 1B). In addition,
Vpr LTNP-04-2 contained the Q65R substitution within the
leucine-rich domain of Vpr, recently shown as deleterious for Vpr
binding to the DCAF1 subunit of the Cul4a/DDB1 E3 ligase
[12–17]. However, this vpr allele was found only in a minor virus
population of the LTNP-04 PBMC sample (Table 1), and no
correlation could be established between this mutation and viral
load or CD4+ T-cell count. Regarding the vpr sequences isolated
from the progressor patient, PR-2 had a substitution of Ser79 in
Gly which is predicted to affect Vpr phosphorylation and its G2-
arrest activity [33,34]. Moreover, PR-3 showed a L64P substitu-
tion also described as precluding G2-arrest [35].
The LTNP-86, LTNP-96 and two predominant alleles from the
2004 sample (LTNP-04-1 and LTNP-04-2), as well as the three
alleles of the progressor patient (PR-1, PR-2 and PR-3), were
selected for further functional characterization.
Subcellular localization of the primary Vpr proteins
HIV-1 Vpr primarily localizes in the nucleus, but also
accumulates at the NE where it co-localizes with components of
the nuclear pore complex, such as the nucleoporin hCG1 (Fig. 2A)
(see Ref. [1] for review). A similar cellular distribution was revealed
for the LTNP-86, -96 and -04-1 proteins, when expressed as Vpr-
GFP fusions (Fig. 2B). Interestingly, the Vpr LTNP-04-2 protein,
containing the Q65R substitution, as well as the VprLai-GFP Q65R
mutant, failed to accumulate at the NE (Fig. 2B), indicating that this
residue participates in the proper localization of Vpr. When
expressed as HA-tagged proteins, these Vpr variants similarly co-
distributed inthe cytoplasm and the nucleus, whereas wt HA-VprLai
was concentrated into the nucleus and at the NE (data not shown).
This observation also indicates that the Vpr/DCAF1 interaction
might be functionally related to the docking of Vpr at the NE.
Among Vpr proteins isolated from the progressor patient, the
minor PR-3 allele (see on Table 1) was found equally distributed
between the cytoplasm and the nucleus (Fig. 2B). However, we
failed to detect the PR-3 protein in transfected T-cells (see below),
suggesting that this variant was rather unstable.
Interaction of primary variants with cellular partners of
Vpr
Vpr properties have been related to its ability to interact with
host cell partners, including the nucleoporin hCG1, the UNG2
enzyme and DCAF1. These cellular proteins were thus analyzed
in the yeast two-hybrid system for interaction with primary Vpr
variants isolated from both LTNP and PR patients. Most of the
variants did interact with hCG1, UNG2 and DCAF1, as visualized
by growth of yeast-transformed cells on medium without histidine
(Fig. 3), arguing for a good conservation of the structural
determinants required for Vpr functions. While no variant had
substitution of the Trp54 residue required for UNG2 binding
[4,5,35], LTNP-04-2 naturally contained the Q65R substitution
and failed to interact with DCAF1, confirming the crucial role of
this residue in mediating Vpr/DCAF1 interaction in the context of
a primary Vpr variant [13,15]. It is noteworthy that the residue 77
had no impact on Vpr binding to hCG1, UNG2 or DCAF1. Like
VprLai and VprLai-R77Q, primary Vpr proteins with an Arg or a
Gln similarly bound to these cellular proteins (Fig. 3). Finally, the
negative results obtained with the PR-3 variant suggested that it
was also poorly expressed in yeast cells.
G2-arrest and cell death induction of Vpr variants
Since the G2-arrest activity and apoptosis induction are the
most documented effects of Vpr in vitro (reviewed in Refs [1,36]),
Vpr variants were assayed in T lymphocytes for these activities
(Fig. 4). Consistent with our previous observations [37], Vpr-
induced apoptosis of all variants (Fig. 4C) strictly paralleled the
results obtained in the G2-arrest experiments (Fig. 4B). As
expected, LTNP-04-2 Vpr, containing the Q65R substitution,
failed to induce G2-arrest when compared to VprLai. Similarly,
PR-2 and PR-3 variants were less efficient than VprLai. While the
lack of activity of PR-3 was due to a problem of expression
(Fig. 4A) that might be consequent to the presence of the
structurally destabilizing L64P mutation [38], the reduced activity
of PR-2 may be related to the S79G substitution, previously shown
as deleterious for this activity [33,34].
The results reported in Fig. 4 confirm that induction of G2-arrest
and apoptosis by Vpr are functionally linked, even if others have
suggested that the G2-arrest was not a prerequisite for induction of
apoptosis [39–41]. Although it was proposed that the HIV-1 LTR
was more active in the G2 phase [18], the significance of this cell
cycle arrest during infection is still not well understood. Neverthe-
less, some studies have demonstrated that p24-positive cells isolated
from infected individuals have a DNAcontent that is consistentwith
G2-arrest [40], indicating that further studies are needed to
understand the role of this well-conserved Vpr function in vivo.
HIV-1 Primary vpr Alleles
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7514Figure 1. Description of patients and vpr alleles analyzed in the study. A) Immunological and viral profiles of the patients analyzed. These
patients were selected from the HIV-1-infected patient cohort of the St-Antoine Hospital (Paris), and the samples were collected with written
informed consent [45,46]. The graphs show the time-course evolution of the blood CD4+ T cell counts (green curves) and plasmatic virus load (viral
RNA, red curves); the PBMC samples analyzed in the present study are indicated by the blue arrows. B) Alignment of the amino acid sequences
derived from DNA sequencing of the vpr alleles cloned from PBMC DNA samples. Excepted for LTNP-05 and LTNP-07 sequences that were obtained
by direct sequencing of the bulk PCR fragments amplified from these samples, at least 40 independent clones were sequenced from each other
samples. The sequences of the primary Vpr proteins are aligned with respect of the prototypic HIV-1Lai sequence (upper sequence). The vpr alleles
from the LNTP (patient 5071) that were selected for subsequent functional analysis are in the box; the R77Q substitution identified in some vpr alleles
is indicated in blue, while the Q65R substitution identified in the Vpr LTNP-04-2 is indicated in red.
doi:10.1371/journal.pone.0007514.g001
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namely LTNP-86 and LTNP-04-1, were even slightly more
efficient for G-2 arrest and pro-apoptotic activities than those
containing an Arg77, including LTNP-96 and PR-1 as well as the
prototypic VprLai (Fig. 4), arguing against a deleterious impact of
the R77Q substitution on Vpr functions [22]. To further analyze
the influence of the R77Q substitution on the proapoptotic activity
of Vpr in the context of the LTNP alleles, we performed a detailed
reverse mutational analysis. While the Gln77 found in LTNP-86
and LNTP-04-1 was mutated to Arg, the Arg77 found in LTNP-
96 was mutated to Gln. As shown in Fig. 5A, the Q77R
substitution of LTNP-86 and LNTP-04-1 resulted in a slightly
reduced ability to induce apoptosis, whereas the R77Q LTNP-96
mutant was more active than the parental variant. Furthermore, a
similar phenotype was observed when the R77Q substitution was
introduced in VprLai. Altogether, these data do not support
previous observations on the critical role of Arg77 for the ability of
Vpr to induce apoptosis [22]. Similarly, the residue in position 77
had no influence on Vpr-mediated G2-arrest (Fig. 5B). In
contradiction with some reports [22,23], we show that the
R77Q substitution, found in the sequence of some vpr alleles from
LTNPs, does not abolish the pro-apoptotic activity of Vpr.
Instead, our data suggest that this substitution have a null to
moderate positive impact on this activity, in agreement with recent
reports showing that introduction of the R77Q mutation in HIV-
1NL4-3 Vpr results in a functional protein [37,42].
One original finding of the present study relies on the
identification, in the context of the natural infection, of a Vpr
variant harboring the Q65R substitution previously reported as
deleterious for DCAF1 binding and consequently for Vpr-induced
cell cycle arrest [12–17]. Moreover, we now report that this
Table 1. Relative frequency of primary Vpr alleles
a.
Samples Vpr alleles
Number of clones/total
number of sequenced clones (%)
Sample 1986 LTNP-86 40/40 (100)
Sample 1996 LTNP-96 40/40 (100)
Sample 2004 LTNP-04-1 23/40 (57.5)
LTNP-04-2 6/40 (15)
LTNP-04-3 3/40 (7.5)
LTNP-04-4 3/40 (7.5)
LTNP-04-5 5/40 (12.5)
Sample PR PR1 18/42 (43)
PR2 18/42 (43)
PR3 6/42 (14)
avpr genes were amplified by PCR from each PBMC sample (indicated by blue
arrows in Fig. 1A), cloned into a shuttle plasmid, and DNA sequences from at
least 40 independent clones were determined from each sample.
bsamples 1986, 1996 and 2004 are from the LTNP patient (5071), and sample PR
is from the progressor patient (1200).
cVpr alleles correspond to the primary amino acid sequences reported in Fig. 1B.
doi:10.1371/journal.pone.0007514.t001
Figure 2. Cellular localization of Vpr proteins from the LTNP and PR patients. (A) Co-localization of VprLai and hCG1 at the NE. HeLa cells
were transiently transfected with vectors for expression of VprLai fused to GPF together with hCG1 fused to the Myc tag. 16 h after transfection, cells
were fixed and subcellular distribution of the fusion proteins was analyzed by epifluorescence microscopy. (B) Subcellular distribution of the
indicated primary Vpr proteins from the LTNP and PR patients fused to GFP. Cells expressing GFP were used as a control.
doi:10.1371/journal.pone.0007514.g002
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mutant, abrogates Vpr docking at the NE, raising the possibility of
a functional link between Vpr accumulation at the NE and its
cytostatic activity. Indeed, it was reported that Vpr expression
induced transient ruptures of the NE, resulting in a mixing of
cytoplasmic and nuclear components that regulate the cell cycle
[39]. As previously discussed [43], Vpr docking at the NE could
constitute a prerequisite for binding to DCAF1 and subsequent
induction of cell cycle arrest. This hypothesis is strengthened by
the observation that almost all Vpr mutants described so far as
disrupting the NE accumulation are altered as well for the G2-
arrest activity [10,19,20,44]. Alternatively, Vpr binding to DCAF1
might be required for proper docking of Vpr at the NE, where it
could then exert its cytostatic activity by means of local
interactions.
Although no correlation between Vpr functionality of dominant
primary alleles and evolution of viral load during HIV-1 infection
could be made from two unique patients, this could be achieved
through large scale longitudinal studies investigating molecular
and functional aspects of HIV-1 Vpr. In the present work, we used
this rational approach to revisit, in the context of the natural
infection, some aspects of Vpr molecular and functional properties
that had been described so far by means of artificially created
mutants. Our findings indicate that Vpr variants from either
LTNP or progressor patients retain most of the functional features
of the HIV-1 Vpr protein previously characterized in different in
vitro systems. Most of the primary Vpr proteins displayed efficient
cytostatic and pro-apoptotic activities when expressed in T
lymphocytes. Although Vpr certainly constitutes an important
determinant of virulence in vivo, the real contribution of both
cytostatic and cytotoxic properties of the protein to the viral
replication and pathogenesis during the course of HIV-1 infection
remains unclear. In addition, our results also open new
perspectives regarding a possible functional link between Vpr
accumulation at the NE and its ability to interact with the DCAF1
subunit of the Cul4a/DDB1 E3 ligase.
Materials and Methods
HIV-1 infected Patients
Based on clinical, virological and immunological status (Fig. 1A),
two patients with a well-documented natural history of infection
Figure 3. Interaction of the Vpr proteins from the LTNP and PR patients with hCG1, UNG2 and DCAF1 in the yeast two-hybrid
system. The L40 reporter yeast strain expressing VprLai or the indicated primary Vpr proteins from the LTNP and PR patients fused to LexA (LexA
hybrid), in combination with either hCG1, UNG2 or DCAF1 fused to the Gal4 activation domain (Gal4AD hybrid), was analyzed for histidine
auxotrophy. Growth in the absence of histidine indicates interaction between hybrid proteins.
doi:10.1371/journal.pone.0007514.g003
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7514Figure 4. G2-arrest and pro-apoptotic activities of Vpr proteins from the LTNP and PR patients. HPB-ALL T lymphoid cells were co-
transfected with vectors for expression of HA tagged VprLai or the indicated primary Vpr proteins from the LTNP and PR patients, in combination
with the GFP expression vector. A) Cellular expression of HA-tagged Vpr proteins. Lysates from HPB-ALL transfected cells were analyzed by western-
blotting using anti-GFP and anti-HA antibodies. B) G2-arrest activity of primary Vpr proteins. 48 h after transfection, cells were fixed and the DNA
content of GFP-positive cells was analyzed by flow cytometry after DNA staining with propidium iodide. Results are expressed as the G2M/G1 ratios
relative to that of the VprLai. C) Pro-apoptotic activity of Vpr proteins. Cells co-expressing the GFP and HA-tagged Vpr proteins were assayed by flow
cytometry 72 h following transfection for cell surface phosphatidylserine exposure using AnnexinV coupled to phycoerythrin. Values are means of
three independent experiments; error bars represent one standard deviation from the mean.
doi:10.1371/journal.pone.0007514.g004
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HIV-1-infected patient cohort of the St-Antoine Hospital, Paris.
These caucasian patients were infected in 1985 with subtype B
viruses. The LTNP patient was still asymptomatic 22 years after
contamination, in the absence of antiretroviral therapy, with
relatively stable CD4 cell counts (.350 cells/mm3) and low levels
of viral RNA for the first 10 years of infection. From 2000 to 2006,
we observed an increase in the copy number of viral RNA
followed by a decrease in the CD4 cell-count [45,46]. Three
samples of frozen peripheral blood mononuclear cells (PBMC) at
different time points (1986, 1996, 2004, 2005 and 2006) were
analyzed. Conversely, the progressor patient was infected in 1985
and rapidly treated by ZDV on the basis of a low level of CD4+ T
lymphocytes (,200 cells/mm3); the PBMC sample analyzed
herein was isolated in 1988, 2 years before the patient died of
AIDS. All the blood samples were collected in a previous
longitudinal study, approved by the ethics committee from the
St-Antoine Hospital (Paris, France), with written informed consent
from infected patients [45,46].
Viral DNA isolation and sequencing
PBMCs were isolated by Ficoll-hypaque density gradient
centrifugation, and viral DNA was extracted using QIAamp
blood extraction kit (QIAGEN). For each sample, 500 ng DNA
were used to amplify vpr genes by two sequential PCR as
previously described [22]. The final PCR product was sub-cloned
into the pCR3.1 plasmid using the TA Cloning kit (Invitrogen)
and subsequently transformed into DH5a Max Efficiency bacteria
(Invitrogen). At least 40 clones were sequenced.
Expression vectors
The primary vpr alleles were subcloned into expression vectors for
further characterization. Vpr g e n e sw e r et h u sa m p l i f i e df r o mt h e
pCR3.1 constructs, using the following primers: VprBam-F-AGTCG-
GATCCATGGAACAAGCCCCAGAAGAC and VprXho-R-ACT
GCTCGAGTCAGGATCTACTGGCTCCATT for subcloning in-
to the pLex10 and pAS1B plasmids as previously described [43] , for
expression of Vpr as a fusion to LexA or to the HA-tag in yeast and
mammalian cells, respectively; VprXho-FACTGCTCGAGCTATG-
GAA CAAGCCCCAGAAGAC and VprBam-R(DTGA)ACTGG-
GATCCGGATCTACTGGCTCCATT for subcloning into pEGFP-
N3 as described [43] for expression of Vpr as fusions to the N-terminal
of the GFP. The vectors for yeast and mammalian expression of hCG1
and UNG2, and the vector for expression of VprR90K were
previously described [9,47]. The vector for yeast expression of DCAF1
was provided by F. Margottin-Goguet (Cochin Institute, Paris) [15].
Site-directed mutagenesis on residue 77 was performed by PCR using
specific primers containing the desired mutations.
Yeast two-hybrid
The L40 yeast reporter strain containing the HIS3 LexA-
inducible genewas cotransformed with the indicated LexABD and
Gal4AD hybrid expression vectors and plated on selective medium
as reported [4,47]. Double transformants were patched on the
same medium and replica plated on selective medium lacking
histidine for auxotrophy analysis as described.
Cell culture and transfections
HeLa cells and CD4-positive HPB-ALL T-cells were main-
tained as previously described [9,48]. HeLa cells were transfected
with the Vpr-GFP constructs alone or in combination with Myc-
hCG1 expression vector using the calcium phosphate method as
described [9]. HPB-ALL cells were electroporated as described
[48] with the GFP expression vector as a transfection marker, and
the HA-Vpr expression vectors.
Immunofluorescence
18 h after transfection, HeLa cells were fixed with 4%
paraformaldehyde (PFA) and permeabilized as described. [9].
Cells expressing Myc-hCG1 were permeabilized with 55 mg/ml
Figure 5. Impact of the residue 77 on pro-apoptotic and G2-arrest activities of Vpr LTNP variants. The Arg77 residue from VprLai and
Vpr LTNP-96 was replaced by a Gln, whereas the Gln residue from LTNP-86 and LTNP-04-1 was replaced by an Arg. The wild-type (grey bars) and
mutated (hatched bars) Vpr proteins were then analyzed for apoptosis (A) and G2-arrest (B) activities as described in Figure 4.
doi:10.1371/journal.pone.0007514.g005
HIV-1 Primary vpr Alleles
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(9E10, Roche) and TexasRed-conjugated anti-mouse IgG (Jack-
son) were use as primary and secondary antibodies, respectively.
Images were acquired with a Leica DMRB epifluorescence
microscope equipped with a CCD camera (Princeton) controlled
by Metamorph V5.0r6 software (Universal Imaging Corp.).
Cell cycle and apoptosis
48 h after transfection, half of HPB-ALL cells were collected
and fixed with PFA 1% as described [43,48]. Cells were then
permeabilized in cold 70% ethanol and incubated with 200 mg/ml
RNAse A and 50 mg/ml propidium iodide. 72 h after transfection,
the remaining HPB-ALL cells were analyzed by flow cytometry for
cell surface phosphatidylserines (PS) using phycoerythrin-conju-
gated annexin V (AnnexinV-PE, Bender MedSystems) as de-
scribed [43,48]. Cell cycle and PS-exposure profiles were analyzed
on GFP-positive cells using a Cytomics FC 500 instrument
(Beckman Coulter).
Protein expression
HPB-ALL cells expressing HA-Vpr proteins together with GFP
were lysed, separated by SDS-PAGE and transferred to a
polyvinylidene difluoride (PVDF) Hybond-P membrane (GE
Healthcare) as described [48]. Membranes were probed with
mouse anti-GFP 7.1–13.1 (1814460, Roche) and rat anti-HA 3F10
(Roche) primary antibodies and with secondary HRP-coupled
anti-mouse and anti-rat antibodies (Sigma).
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